CAB39

Summary

CAB39 (calcium binding protein 39, HGNC:20292) is a protein-coding gene on chromosome 2q37.1, encoding Calcium-binding protein 39 (Q9Y376). Component of a complex that binds and activates STK11/LKB1. It is a selective cancer dependency (DepMap: 23.1% of cell lines).

Enables kinase binding activity and protein serine/threonine kinase activator activity. Involved in intracellular signal transduction; peptidyl-serine phosphorylation; and positive regulation of protein phosphorylation. Located in cytoplasm. Part of serine/threonine protein kinase complex. Implicated in hepatocellular carcinoma. Biomarker of hepatocellular carcinoma and pancreatic cancer.

Source: NCBI Gene 51719 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 28 total — 1 pathogenic
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 23.1% of screened cell lines
• MANE Select transcript: NM_016289

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20292
Approved symbol	CAB39
Name	calcium binding protein 39
Location	2q37.1
Locus type	gene with protein product
Status	Approved
Aliases	CGI-66, MO25
Ensembl gene	ENSG00000135932
Ensembl biotype	protein_coding
OMIM	612174
Entrez	51719

Gene structure

Transcript identifiers

Ensembl transcripts: 28 — 25 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000258418, ENST00000409788, ENST00000410084, ENST00000478152, ENST00000484398, ENST00000493540, ENST00000874559, ENST00000874560, ENST00000874561, ENST00000874562, ENST00000874563, ENST00000874564, ENST00000874565, ENST00000874566, ENST00000874567, ENST00000874568, ENST00000874569, ENST00000874570, ENST00000913362, ENST00000913363, ENST00000913364, ENST00000913365, ENST00000913366, ENST00000962335, ENST00000962336, ENST00000962337, ENST00000962338, ENST00000962339

RefSeq mRNA: 3 — MANE Select: NM_016289 NM_001130849, NM_001130850, NM_016289

CCDS: CCDS2478

Canonical transcript exons

ENST00000258418 — 9 exons

Exon	Start	End
ENSE00000922487	230790872	230791036
ENSE00000922489	230810263	230810322
ENSE00000922490	230814049	230814114
ENSE00000965552	230798729	230798897
ENSE00001154635	230712842	230713230
ENSE00001174706	230818516	230821075
ENSE00001174710	230759959	230760115
ENSE00001722339	230817754	230817897
ENSE00003504728	230793213	230793331

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 98.86.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 37.1960 / max 387.5476, expressed in 1822 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
25822	34.4618	1820
25826	1.4704	714
25823	1.2121	514
25825	0.0518	22

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
amniotic fluid	UBERON:0000173	98.86	gold quality
esophagus squamous epithelium	UBERON:0006920	98.82	gold quality
tibia	UBERON:0000979	98.32	gold quality
middle temporal gyrus	UBERON:0002771	98.31	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.16	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.13	gold quality
biceps brachii	UBERON:0001507	97.98	gold quality
mucosa of sigmoid colon	UBERON:0004993	97.86	gold quality
palpebral conjunctiva	UBERON:0001812	97.83	gold quality
gluteal muscle	UBERON:0002000	97.75	gold quality
colonic mucosa	UBERON:0000317	97.73	gold quality
cartilage tissue	UBERON:0002418	97.69	gold quality
epithelium of esophagus	UBERON:0001976	97.52	gold quality
triceps brachii	UBERON:0001509	97.26	gold quality
eye	UBERON:0000970	97.11	gold quality
medial globus pallidus	UBERON:0002477	97.11	gold quality
squamous epithelium	UBERON:0006914	97.08	gold quality
oral cavity	UBERON:0000167	96.94	gold quality
skeletal muscle tissue	UBERON:0001134	96.89	gold quality
trabecular bone tissue	UBERON:0002483	96.88	gold quality
muscle of leg	UBERON:0001383	96.79	gold quality
muscle organ	UBERON:0001630	96.72	gold quality
skeletal muscle organ	UBERON:0014892	96.72	gold quality
gastrocnemius	UBERON:0001388	96.71	gold quality
epithelium of nasopharynx	UBERON:0001951	96.71	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.70	gold quality
vastus lateralis	UBERON:0001379	96.64	gold quality
pons	UBERON:0000988	96.62	gold quality
visceral pleura	UBERON:0002401	96.60	gold quality
jejunal mucosa	UBERON:0000399	96.59	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	32.03
E-ANND-3	yes	9.86

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

162 targeting CAB39, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-1468-3P	99.96	72.74	3797

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 23.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 15)

• STRADalpha.MO25alpha complexes containing LKB1 variants were equally effective at phosphorylating and activating AMPK, BRSK1, and BRSK2 (PMID:18854318)
• These data define a brush border induction pathway downstream of the Lkb1/Strad/Mo25 polarization complex, yet separate from other polarity events. (PMID:19386264)
• ATP and MO25alpha cooperate to maintain STRADalpha in an “active” closed conformation required for LKB1 activation. (PMID:19513107)
• study describes structure of the core heterotrimeric LKB1-STRADalpha-MO25alpha complex, revealing an unusual allosteric mechanism of LKB1 activation; structure also reveals how mutations in Peutz-Jeghers syndrome & sporadic cancers impair LKB1 function (PMID:19892943)
• MO25 is a master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein kinases. (PMID:21423148)
• Authors conclude that miR-451 represses glioma in vitro and in vivo, likely through targeting CAB39 directly and inhibiting the PI3K/AKT pathway indirectly. (PMID:22179124)
• These data provide molecular understanding of the mechanism by which MO25 isoforms regulates the activity of STE20 family protein kinases. (PMID:23296203)
• plays very important oncogenic roles in hepatocellular carcinoma pathogenesis and progression by activating the ERK signaling pathway (PMID:28605041)
• The MO25 binding to SPAK and OSR1 is enhanced by serine phosphorylation in their highly conserved WEWS motif, which is located in their C-terminal domains. (PMID:30060950)
• Upregulation of miR-451 expression suppressed the growth and invasion of glioma cells in vitro and in vivo by targeting CAB39 and modulating the mTOR/HIF-1a/VEGF signaling pathway. (PMID:30180756)
• miR-1265 suppresses gastric cancer progression and oncogenic autophagy by reducing CAB39 expression and regulating the AMPK-mTOR signaling pathway. (PMID:30779944)
• MiR-107 confers chemoresistance to colorectal cancer by targeting calcium-binding protein 39. (PMID:31919406)
• miR-107 inhibition upregulates CAB39 and activates AMPK-Nrf2 signaling to protect osteoblasts from dexamethasone-induced oxidative injury and cytotoxicity. (PMID:32527986)
• CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway. (PMID:37726090)
• miR-451a was selectively sorted into exosomes and promoted the progression of esophageal squamous cell carcinoma through CAB39. (PMID:38649419)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	cab39	ENSDARG00000043451
mus_musculus	Cab39	ENSMUSG00000036707
rattus_norvegicus	Cab39	ENSRNOG00000017297
drosophila_melanogaster	Mo25	FBGN0017572
caenorhabditis_elegans		WBGENE00013140
caenorhabditis_elegans		WBGENE00019827

Paralogs (1): CAB39L (ENSG00000102547)

Protein

Protein identifiers

Calcium-binding protein 39 — Q9Y376 (reviewed: Q9Y376)

Alternative names: MO25alpha, Protein Mo25

All UniProt accessions (1): Q9Y376

UniProt curated annotations — full annotation on UniProt →

Function. Component of a complex that binds and activates STK11/LKB1. In the complex, required to stabilize the interaction between CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta) and STK11/LKB1.

Subunit / interactions. Component of a trimeric complex composed of STK11/LKB1, STRAD (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta): the complex tethers STK11/LKB1 in the cytoplasm and stimulates its catalytic activity.

Subcellular location. Cytoplasm.

Similarity. Belongs to the Mo25 family.

RefSeq proteins (3): NP_001124321, NP_001124322, NP_057373* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011989	ARM-like	Homologous_superfamily
IPR013878	Mo25	Family
IPR016024	ARM-type_fold	Homologous_superfamily

Pfam: PF08569

UniProt features (32 total): helix 25, mutagenesis site 2, turn 2, strand 2, chain 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
1UPK	X-RAY DIFFRACTION	1.85
3GNI	X-RAY DIFFRACTION	2.35
1UPL	X-RAY DIFFRACTION	2.6
2WTK	X-RAY DIFFRACTION	2.65
8VSU	ELECTRON MICROSCOPY	2.86
4FZA	X-RAY DIFFRACTION	3.15
4O27	X-RAY DIFFRACTION	3.19
4FZD	X-RAY DIFFRACTION	3.25
4NZW	X-RAY DIFFRACTION	3.58
4FZF	X-RAY DIFFRACTION	3.64

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y376-F1	94.77	0.92

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (2):

Position	Phenotype
240	abolishes activation of stk11/lkb1; when associated with a-243.
243	abolishes activation of stk11/lkb1; when associated with a-240.

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-380972	Energy dependent regulation of mTOR by LKB1-AMPK
R-HSA-6798695	Neutrophil degranulation
R-HSA-162582	Signal Transduction
R-HSA-165159	MTOR signalling
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 279 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GOBP_POTASSIUM_ION_TRANSPORT, GOBP_NEGATIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, REACTOME_INNATE_IMMUNE_SYSTEM, TGCGCANK_UNKNOWN, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOCC_SECRETORY_GRANULE, CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN, KYNG_DNA_DAMAGE_DN, GOBP_MONOATOMIC_CATION_TRANSPORT, GOMF_KINASE_ACTIVATOR_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_TRANSPORT, CATTTCA_MIR203, GOBP_NEGATIVE_REGULATION_OF_POTASSIUM_ION_TRANSPORT, MODULE_239

GO Biological Process (6): signal transduction (GO:0007165), response to activity (GO:0014823), intracellular signal transduction (GO:0035556), cellular hypotonic response (GO:0071476), response to thyroid hormone (GO:0097066), negative regulation of potassium ion transmembrane transport (GO:1901380)

GO Molecular Function (5): kinase binding (GO:0019900), protein kinase activator activity (GO:0030295), protein serine/threonine kinase activator activity (GO:0043539), protein serine/threonine kinase binding (GO:0120283), protein binding (GO:0005515)

GO Cellular Component (9): extracellular region (GO:0005576), cytoplasm (GO:0005737), cytosol (GO:0005829), Z disc (GO:0030018), secretory granule lumen (GO:0034774), extracellular exosome (GO:0070062), serine/threonine protein kinase complex (GO:1902554), ficolin-1-rich granule lumen (GO:1904813), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
MTOR signalling	1
Innate Immune System	1
Signal Transduction	1
Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
intracellular anatomical structure	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
response to stimulus	1
signal transduction	1
hypotonic response	1
cellular response to osmotic stress	1
response to hormone	1
negative regulation of potassium ion transport	1
potassium ion transmembrane transport	1
regulation of potassium ion transmembrane transport	1
negative regulation of cation transmembrane transport	1
enzyme binding	1
protein kinase activity	1
kinase activator activity	1
protein kinase regulator activity	1
protein serine/threonine kinase activity	1
protein kinase activator activity	1
protein kinase binding	1
binding	1
cytoplasm	1
I band	1
secretory granule	1
cytoplasmic vesicle lumen	1
extracellular vesicle	1
protein kinase complex	1
intracellular organelle lumen	1
ficolin-1-rich granule	1
cellular_component	1

Protein interactions and networks

STRING

1042 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CAB39	STK11	Q15831	999
CAB39	STRADA	Q7RTN6	999
CAB39	STRADB	Q9C0K7	976
CAB39	STK24	Q9Y6E0	905
CAB39	STK25	O00506	837
CAB39	SNRK	Q9NRH2	811
CAB39	STK39	Q9UEW8	790
CAB39	OXSR1	O95747	715
CAB39	STK26	Q9P289	636
CAB39	DUSP5	Q16690	550
CAB39	HEY2	Q9UBP5	550
CAB39	CAMKK2	Q96RR4	542
CAB39	STK11IP	Q8N1F8	520
CAB39	BRSK1	Q8TDC3	512
CAB39	MYC	P01106	496

IntAct

131 interactions, top by confidence:

A	B	Type	Score
STK11	STRADA	psi-mi:“MI:0914”(association)	0.960
STK11	CAB39	psi-mi:“MI:0915”(physical association)	0.950
CAB39	STK11	psi-mi:“MI:0914”(association)	0.950
CAB39	STK11	psi-mi:“MI:0915”(physical association)	0.950
CAB39	STK11	psi-mi:“MI:2364”(proximity)	0.950
STK11	FKBP5	psi-mi:“MI:0914”(association)	0.910
STK25	STRN	psi-mi:“MI:0914”(association)	0.900
CAB39	STRADB	psi-mi:“MI:0915”(physical association)	0.770
STRADB	CAB39	psi-mi:“MI:0403”(colocalization)	0.770
STRADB	CAB39	psi-mi:“MI:0915”(physical association)	0.770
STK11	HSP90AA1	psi-mi:“MI:0914”(association)	0.740
STK25	CAB39	psi-mi:“MI:0915”(physical association)	0.740
STRADA	CAB39	psi-mi:“MI:0407”(direct interaction)	0.730
STRADA	CAB39	psi-mi:“MI:0915”(physical association)	0.730
CAB39	STRADA	psi-mi:“MI:0915”(physical association)	0.730

BioGRID (112): CAB39 (Affinity Capture-MS), CAB39 (Affinity Capture-MS), CAB39 (Affinity Capture-MS), CAB39 (Affinity Capture-MS), CAB39 (Affinity Capture-MS), CAB39 (Affinity Capture-MS), AP2B1 (Co-fractionation), CAB39 (Co-fractionation), CAB39 (Co-fractionation), CAB39 (Co-fractionation), CAB39 (Co-fractionation), CAB39 (Co-fractionation), CAB39 (Co-fractionation), CAB39 (Co-fractionation), CAB39 (Co-fractionation)

ESM2 similar proteins: A5D785, F4IZR5, O18211, O35643, O62703, P45437, P52292, P52293, P52303, P55060, P62944, P63009, P63010, P91891, P91926, Q06138, Q08DS7, Q10567, Q26626, Q29G21, Q29N38, Q29RI6, Q2HJG5, Q4S6U8, Q4V8K2, Q5R9J2, Q66HV4, Q6DFT3, Q6IN85, Q6P2K6, Q7KLV9, Q7QG73, Q7ZX60, Q801Q7, Q8AY73, Q8W207, Q8WYA6, Q96QK1, Q9CWL8, Q9DB16

Diamond homologs: O18211, O60032, P32464, P91891, Q06138, Q29RI6, Q9DB16, Q9FGK3, Q9H9S4, Q9M0M4, Q9P7Q8, Q9XFY6, Q9Y376, Q9ZQ77

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 77 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
protein autophosphorylation	6	12.4×	2e-03
protein phosphorylation	7	6.8×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

28 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	13
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1526961	GRCh37/hg19 2q36.3-37.1(chr2:229968217-231883182)	Pathogenic

SpliceAI

1990 predictions. Top by Δscore:

Variant	Effect	Δscore
2:230713226:GCCCC:G	donor_gain	1.0000
2:230759951:T:TA	acceptor_gain	1.0000
2:230759957:A:AG	acceptor_gain	1.0000
2:230759958:G:GG	acceptor_gain	1.0000
2:230759958:GGT:G	acceptor_gain	1.0000
2:230759958:GGTA:G	acceptor_gain	1.0000
2:230760113:AAGGT:A	donor_loss	1.0000
2:230760116:G:GC	donor_loss	1.0000
2:230760116:G:GG	donor_gain	1.0000
2:230760117:T:A	donor_loss	1.0000
2:230790851:A:AG	acceptor_gain	1.0000
2:230790864:A:AG	acceptor_gain	1.0000
2:230790865:A:G	acceptor_gain	1.0000
2:230790866:A:AG	acceptor_gain	1.0000
2:230791033:TGAGG:T	donor_loss	1.0000
2:230791034:GAG:G	donor_gain	1.0000
2:230791035:AGGTA:A	donor_loss	1.0000
2:230791036:GGTA:G	donor_loss	1.0000
2:230791037:G:GG	donor_gain	1.0000
2:230791037:GTAA:G	donor_loss	1.0000
2:230791038:T:G	donor_loss	1.0000
2:230798723:TTGCA:T	acceptor_loss	1.0000
2:230798724:TGCA:T	acceptor_loss	1.0000
2:230798725:GCAGG:G	acceptor_loss	1.0000
2:230798726:CAG:C	acceptor_loss	1.0000
2:230798728:G:GC	acceptor_loss	1.0000
2:230798893:TCAAG:T	donor_loss	1.0000
2:230798894:CAAG:C	donor_loss	1.0000
2:230798895:AAGGT:A	donor_loss	1.0000
2:230798896:AG:A	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000015704 (2:230813230 G>C), RS1000042018 (2:230803763 G>A), RS1000054590 (2:230722620 A>T), RS1000100281 (2:230756279 A>G,T), RS1000108818 (2:230797617 C>G), RS1000137238 (2:230783847 A>G), RS1000146274 (2:230765830 G>A,T), RS1000154554 (2:230716860 C>T), RS1000156576 (2:230725500 C>A,T), RS1000164277 (2:230765995 A>C,T), RS1000237397 (2:230731605 T>A), RS1000271126 (2:230797935 G>T), RS1000286279 (2:230778725 C>T), RS1000316486 (2:230719859 T>C), RS1000316582 (2:230759932 T>G)

Disease associations

OMIM: gene MIM:612174 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2010621 (SINGLE PROTEIN), CHEMBL3885534 (PROTEIN COMPLEX)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.11	Kd	7.818	nM	CHEMBL5653589
8.11	ED50	7.818	nM	CHEMBL5653589
6.80	Kd	157.3	nM	CHEMBL3752910
6.80	ED50	157.3	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 9 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147976: Binding affinity to human CAB39 incubated for 45 mins by Kinobead based pull down assay	kd	0.0078	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147976: Binding affinity to human CAB39 incubated for 45 mins by Kinobead based pull down assay	kd	0.1573	uM

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression	2
Tobacco Smoke Pollution	increases expression, affects expression	2
dicrotophos	decreases expression	1
geldanamycin	increases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	decreases expression	1
benzo(e)pyrene	decreases methylation	1
K 7174	increases expression	1
abrine	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression	1
bisphenol S	increases methylation, affects cotreatment	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Vehicle Emissions	decreases reaction, increases expression	1
Benzo(a)pyrene	affects methylation	1
Calcitriol	increases expression	1
Camptothecin	decreases expression	1
Daunorubicin	decreases expression	1
Doxorubicin	decreases expression	1
Etoposide	decreases expression	1
Ivermectin	decreases expression	1
Methapyrilene	decreases methylation	1
Methyl Methanesulfonate	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Ribonucleotides	affects binding	1
Rotenone	increases expression	1
Smoke	decreases expression	1
Thiram	increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651018	Binding	Binding affinity to human CAB39 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.